Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 3/20 | 0.50 |
| ▸ | PLAA | Q9Y263 | 2/20 | 0.50 |
| ▸ | ALPG | P10696 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PLA2G4A | P47712 | 3/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | QPCT | Q16769 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6306236 | 0.76 | CYP19A1 (0.50) | PLAAALPGALDH1A1 | |
| SCHEMBL4832580 | 0.72 | ALPL (0.54) | ALPLPLAAALPGALDH1A1QPCT | |
| SCHEMBL11997951 | 0.72 | ALPL (0.54) | ALPLPLAAALPGALDH1A1QPCT | |
| SCHEMBL8231599 | 0.72 | ALPL (0.51) | ALPLPLAAALPGALDH1A1PLA2G4A | |
| SCHEMBL4969959 | 0.71 | ALPL (0.65) | ALPLPLAAALPGKMT2A | |
| SCHEMBL1178916 | 0.71 | ALPL (0.53) | ALPLPLAAALPGQPCTKMT2A | |
| SCHEMBL3504222 | 0.70 | — | — | |
| SCHEMBL460767 | 0.69 | ALPL (0.66) | ALPLPLAAALPGPKM | |
| SCHEMBL2961993 | 0.68 | ALPL (0.50) | ALPLPLAAALPGALDH1A1QPCT | |
| SCHEMBL27690636 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-16 | — | — | US | disclosed |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-02 | — | — | US | disclosed |
| US-6342765-B1 | COMPOUNDS THAT INHIBIT FARNESYLATION OF MUTANT RAS GENE PRODUCTS; TREATING DISEASES, ESPECIALLY CANCER, WHICH ARE MEDIATED THROUGH FARNESYLATION OF RAS | ASTRAZENECA UK LIMITED (GB) | 2002-01-29 | — | — | US | disclosed |
| EP-1025088-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | ALPL 3537/4885PLAA 2556/4885ALPG 3769/4885 |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | ALPL 3522/4885PLAA 2507/4885ALPG 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.